Dova Pharmaceuticals to Present at Leerink Partners 7th Annual Global Healthcare Conference

DURHAM, N.C., Feb. 12, 2018 -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the Leerink Partners 7^th Annual Global Healthcare Conference on Wednesday, February 14, 2018 at 3:30 p.m. EST in New York City.

A live audio webcast of the event will be available via the "Investor Relations" page of the Dova website, www.dova.com. Please log on through Dova's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Dova's website for 90 days following the call.

About Dova Pharmaceuticals, Inc.

Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova’s lead drug candidate, avatrombopag, has successfully completed two pivotal Phase 3 clinical trials for the treatment of thrombocytopenia in patients with CLD scheduled to undergo a procedure and an NDA has been accepted for priority review by FDA for this initial indication with a PDUFA goal date of May 21, 2018.

Contacts

Mark W. Hahn
(919) 338-7936
[email protected]

Westwicke Partners
John Woolford
(443) 213-0506
[email protected]